Key Points:

• Oura postponed its planned $2.2 billion U.S. IPO, removing one of the largest prospective offerings from the fall calendar as market volatility and higher bond yields weighed on new-issue conditions.
• The October 1 IPO calendar shows seven expected pricing events, but the lineup includes ETFs, trusts and other transactions, making the headline count a weaker measure of traditional operating-company IPO activity.
• Chilwa Minerals priced a $3.5 million Nasdaq ADS offering, while Vylor began its separation from Corteva, adding smaller listings and a major spin-off to the day’s U.S. equity issuance activity.

Oura Delay Becomes the Market’s Clearest Demand Signal

The U.S. IPO market entered October with a more selective backdrop after Oura postponed its planned Nasdaq debut. The smart-ring maker had been preparing to sell 50 million shares at $40 to $44 each, potentially raising about $2.2 billion, but delayed the offering on September 29 amid market uncertainty. Reuters reported that rising bond yields, interest-rate concerns and broader market volatility contributed to the decision.

The timing matters because Oura was positioned as one of the largest and more closely watched consumer-technology offerings of the fall. Its decision to wait provides a direct indication that a company can have substantial investor interest while still determining that prevailing market conditions do not justify proceeding.

Seven Calendar Events Do Not Equal Seven Traditional IPOs

The October 1 calendar shows seven expected pricing events, including Chilwa Minerals, Encore Medical, MiniMed Group, several investment vehicles and Vylor. The composition requires some qualification: not every calendar entry represents a conventional primary IPO.

Vylor, for example, is becoming a publicly traded company through Corteva’s planned separation of its seed business rather than through a conventional cash-raising IPO. Corteva distributed Vylor shares to its shareholders, with regular-way trading expected to begin on the NYSE under VYLR on October 1.

MiniMed also illustrates why calendar counts need context. Its original IPO was completed earlier in 2026, while the October 1 entry relates to the company’s subsequent market structure and when-issued trading surrounding its separation from Medtronic. Nasdaq confirmed an anticipated October 1 first trade for the when-issued MMEDV security.

Chilwa Adds Capital-Market Activity but at a Smaller Scale

Chilwa Minerals provides the clearest conventional offering associated with the October 1 calendar. The Australian mineral exploration company priced 625,000 American Depositary Shares at $5.60 each, together with warrants, generating approximately $3.5 million in gross proceeds. The ADSs were expected to begin trading on the Nasdaq Capital Market under CHWM on October 1, while the company’s ordinary shares continue trading in Australia.

The transaction is small compared with the multibillion-dollar offerings that can materially influence the broader IPO market. Its significance instead lies in the continued ability of smaller issuers to access U.S. equity markets even while larger transactions face greater scrutiny over valuation and timing.

Oura’s Postponement Keeps Valuation Discipline in Focus

Oura’s proposed offering had called for 13.5 million shares from the company and 36.5 million shares from existing shareholders, meaning most of the shares offered would have come from current holders rather than new capital raised by Oura. The SEC filing also showed an expected price range of $40 to $44 and 320.9 million shares outstanding after the offering.

That structure made the IPO an important test not only of demand for Oura itself but also of how much valuation the public market was prepared to support for a fast-growing consumer technology company. The postponement means that test has been deferred rather than resolved.

What the IPO Market Is Watching Next

The next test for U.S. issuance will be whether postponed deals return with their original valuation expectations intact or adjust their terms before coming back to market. Investors will also watch the performance of newly listed companies and whether smaller offerings can maintain access to public capital. With Oura temporarily removed from the calendar, the market has fewer large transactions through which to measure institutional risk appetite, placing greater importance on upcoming pricing decisions and aftermarket performance.